Aurora Therapeutics, the first startup focused on bespoke CRISPR therapies, laid off staff and stopped its lead program. The company’s work centered on CRISPR base editing to correct mutations, but it is now signaling a pause in the core direction that differentiated it from more conventional, standardized gene editing developers. The development highlights the financing and operational pressure faced by early clinical gene editing startups, particularly those building individualized approaches that can raise manufacturing, regulatory, and development complexity. For the field, Aurora’s move underlines that even with gene-editing differentiation, timelines and clinical validation costs remain decisive for whether custom platforms sustain momentum.